GANX Gain Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GANX

Price (delayed)

$1.855

Market cap

$79.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.58

Enterprise value

$63.26M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 14
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new ...

Highlights
The EPS has grown by 33% YoY and by 4.9% from the previous quarter
GANX's equity has soared by 142% year-on-year but it is down by 25% since the previous quarter
GANX's quick ratio has soared by 137% YoY but it is down by 32% QoQ
The net income is down by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.gaintherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of GANX

GANX stock price

How has the Gain Therapeutics stock price performed over time
Intraday
3.63%
1 week
-8.17%
1 month
-2.37%
1 year
-6.78%
YTD
-42.39%
QTD
-4.38%

Financial performance

How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.69M
Net income
-$21.24M
Gross margin
N/A
Net margin
N/A
GANX's operating income is down by 5% QoQ but it is up by 3.2% YoY
The net income is down by 5% since the previous quarter

Price vs fundamentals

How does GANX's price correlate with its fundamentals

Growth

What is Gain Therapeutics's growth rate over time

Valuation

What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
5.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 33% YoY and by 4.9% from the previous quarter
GANX's equity has soared by 142% year-on-year but it is down by 25% since the previous quarter
The stock's price to book (P/B) is 42% less than its last 4 quarters average of 9.3 but 8% more than its 5-year quarterly average of 5.0

Efficiency

How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has increased by 19% YoY and by 15% QoQ
GANX's return on assets is up by 7% year-on-year and by 7% since the previous quarter

Dividends

What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GANX.

Financial health

How did Gain Therapeutics financials performed over time
GANX's quick ratio has soared by 137% YoY but it is down by 32% QoQ
GANX's current ratio has surged by 111% year-on-year but it is down by 29% since the previous quarter
Gain Therapeutics's debt is 95% lower than its equity
GANX's equity has soared by 142% year-on-year but it is down by 25% since the previous quarter
GANX's debt to equity has dropped by 50% year-on-year but it is up by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.